MedTrace Logo

Comparison of DSM-IV-TR and DSM-5 for ASD

NCT02296502 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 439

Last updated 2019-03-11

Study results available
· View outcomes & findings →

Summary

The study aim is to prospectively compare DSM-IV-TR and DSM-5 criteria for Autism Spectrum Disorder (ASD) in a sample of 250 children and adolescents who meet DSM-IV-TR criteria for ASD and 150 children and adolescents referred for diagnosis who do not meet DSM-IV-TR criteria.Families and children will be recruited from eight sites affiliated with the Autism Treatment Network (ATN). Participants must be between the ages of 2.0 and 17.11 years who undergo an ATN assessment at one of the eight sites. Both subjects who are found to meet criteria of ASD/PDD and those who do not meet criteria (after completing the ATN assessment) will be enrolled. After completing the standard ATN assessment, clinicians will complete a DSM-IV and DSM-5 checklist for ASD/PDD.

Conditions

Interventions

OTHER

DSM

Comparing use of DSM-IV versus DSM-5 criteria for autism spectrum disorder

Sponsors & Collaborators

  • University of Missouri-Columbia

    collaborator OTHER

  • Children's Hospital Los Angeles

    collaborator OTHER

  • Nationwide Children's Hospital

    collaborator OTHER

  • Children's Hospital Medical Center, Cincinnati

    collaborator OTHER

  • Vanderbilt University

    collaborator OTHER

  • University of Pittsburgh

    lead OTHER

Principal Investigators

  • Benjamin Handen, PhD · University of Pittsburgh

Eligibility

Min Age
2 Years
Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-11-30
Primary Completion
2016-11-30
Completion
2016-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02296502 on ClinicalTrials.gov